EE183 Cost-Effectiveness Model for PTAH Oral Immunotherapy in Peanut Allergy Using Two-Year Extension Trial Data

The Institute for Clinical and Economic Review (ICER) published a report of the cost-effectiveness of peanut allergy immunotherapy treatment AR-101 (Peanut (Arachis hypogaea) Allergen Powder-dnfp, “PTAH”) compared to avoidance alone in 2019. PTAH was approved by the FDA in 2020 and two-year extension trial data is now available. Our objective was to replicate and update the previously developed ICER model for PTAH to include extension trial data and updates to drug costs.